Key result
Calcium antagonists fail to reduce AMI infarct size, but diltiazem may lower post-AMI angina and reinfarction.
Why the study?
Do calcium antagonists improve clinical outcomes or reduce infarct size in patients with acute myocardial infarction?
Do calcium antagonists improve clinical outcomes or reduce infarct size in patients with acute myocardial infarction?
Despite theoretical rationale, calcium antagonists have not been shown to reduce infarct size in AMI, though specific agents like diltiazem may have a role in reducing early angina and reinfarction.
Calcium antagonists unsupported for infarct size reduction in AMI; leaves open possible short-term diltiazem benefit requiring confirmation.
Calcium antagonists have proved effective in stable angina, unstable angina and vasospastic angina. However, despite a strong theoretical rationale for their use and promising experimental data, these agents have not reduced infarct size in acute myocardial infarction (AMI) in the large clinical trials performed to date. Their role as adjunctive therapy in combination with reperfusion needs to be examined. Diltiazem has been demonstrated to reduce angina and reinfarction in the 2-week period after AMI in patients receiving multidrug therapy. Results of the single large trial of a calcium antagonist (verapamil) for secondary prevention after AMI were negative; however, several well-designed studies are currently ongoing.
No takes yet. Share an insight, caveat, or question.
David L. Pearle (1988) conducted a review in Acute myocardial infarction. Calcium antagonists was evaluated. Calcium antagonists have not reduced infarct size in acute myocardial infarction in large clinical trials, though diltiazem may reduce angina and reinfarction in the 2-week post-AMI period.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: